Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial).

Journal:

Diabetes Care

Published:

2025-09-20

DOI:

10.2337/dc25-1673

Affiliations:

18

Authors:

15

Go to article

Institutions	Authors	Share
Bayer, Germany	3.000000	0.20
The University of Tokyo (UTokyo), Japan	1.000000	0.07
Washington University in St. Louis (WUSTL), United States of America (USA)	1.000000	0.07
The University of North Carolina at Chapel Hill (UNC), United States of America (USA)	1.000000	0.07
Velocity Clinical Research, United States of America (USA)	1.000000	0.07
Duke University Health System, United States of America (USA)	1.000000	0.07
University Medical Center Groningen (UMCG), RUG, Netherlands	1.000000	0.07
Bayer HealthCare, China	1.000000	0.07
Bayer U.S., United States of America (USA)	1.000000	0.07
KfH-Zentrum in München-Schwabing, Germany	0.500000	0.03
Steno Diabetes Center Copenhagen (SDCC), Denmark	0.500000	0.03
University of Erlangen-Nuremberg (FAU), Germany	0.500000	0.03
Brigham and Women's Hospital (BWH), United States of America (USA)	0.500000	0.03
University of Copenhagen (UCPH), Denmark	0.500000	0.03
Richard L. Roudebush VA Medical Center, United States of America (USA)	0.500000	0.03
Indiana University (IU), United States of America (USA)	0.500000	0.03
Harvard Medical School (HMS), United States of America (USA)	0.500000	0.03

Interested in Clinical Sciences?